임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 02:08
논문번호 151
논문제목(영문) Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Sabaté M,
교신저자명 Sabaté M,
공동저자명 Sabaté M, Brugaletta S, Abizaid A, Banning A, Bartorelli A, Džavík V, Ellis S, Holmes D, Gao R, Jeong MH, Legrand V, Neumann FJ, Nyakern M, Spaulding C, Stoll HP, Worthley S, Urban P; e-SELECT Investigators;
게제년월일 2013-03-17
ISSN 0167-5273
Impact Factor 4.036
학술지명 International Journal of Cardiology
서지사항 0집 / 168권 / 3호,   페이지(2522 - 2527)
요약초록문
(Abstract) 입력		 BACKGROUND:
Outcome of sirolimus-eluting stent (SES) in patients treated with an antivitamin K (VKA) agent before the PCI procedure is unknown.
METHODS:
A total of 7651 patients were selected among 15,147 recipients of SES, included in the worldwide e-SELECT registry, only from those centers which included at least one patient requiring VKA: 296 were pretreated with a VKA agent (VKA group), whereas 7355 patients from the same enrolling medical centers were not (NON-VKA group). The rates of 1) major adverse cardiac events (MACE), including all-cause deaths, myocardial infarction (MI) and target lesion revascularization, 2) stent thrombosis (ST) and 3) major bleeding (MB) in the 2 study groups were compared at 1, 6 and 12 months.
RESULTS:
The patients in VKA group were on average older as compared to those in NON-VKA group (67.7 ± 9.9 vs.62.9 ± 10.7, P<0.001). The indications for pre-procedural anticoagulation were atrial fibrillation in 177 (59.8%), presence of a prosthetic valve in 21 (7.1%), embolization of cardiac origin in 17 (5.7%), pulmonary embolism or deep vein thrombosis in 17 (5.7%), and miscellaneous diagnoses in 64 (21.6%) patients. At 1 year, the rates of MACE and MB were higher in the VKA vs. the NON-VKA group (8.3% and 3% vs. 5.3% and 1.2%, P<0.04 and P<0.002, respectively). The 1-year rates of definite and probable ST were remarkably low in both groups (0.38% vs. 1.1%, p=0.4).
CONCLUSIONS:
Selected patients anticoagulated with VKA agent may safely undergo SES implantation. Those patients may receive a variety of APT regimen at the cost of a moderate increased risk of MB.
파일  C151.+Int+J+Cardiol.+2013;168(3)2522-2527..pdf (745.4K) DATE : 2021-05-26 10:00:14